BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wong DP, Roy NK, Zhang K, Anukanth A, Asthana A, Shirkey-Son NJ, Dunmire S, Jones BJ, Lahr WS, Webber BR, Moriarity BS, Caimi P, Parameswaran R. A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers. Nat Commun 2022;13:217. [PMID: 35017485 DOI: 10.1038/s41467-021-27853-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Huang J, Huang X, Huang J. CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies. Front Immunol 2022;13:1019115. [DOI: 10.3389/fimmu.2022.1019115] [Reference Citation Analysis]
2 Ma R, Liu X, Chang Y. Allogeneic haematopoietic stem cell transplantation for acute lymphoblastic leukaemia: current status and future directions mainly focusing on a Chinese perspective. Expert Review of Hematology. [DOI: 10.1080/17474086.2022.2125375] [Reference Citation Analysis]
3 Gurney M, O'reilly E, Corcoran S, Brophy S, Krawczyk J, Otto NM, Hermanson DL, Childs RW, Szegezdi E, O'dwyer ME. Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor–natural killer cells. Cytotherapy 2022. [DOI: 10.1016/j.jcyt.2022.07.008] [Reference Citation Analysis]
4 Zhang X, Zhu L, Zhang H, Chen S, Xiao Y. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. Front Immunol 2022;13:927153. [PMID: 35757715 DOI: 10.3389/fimmu.2022.927153] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]